TriOar

TriOar is a South Korea-based private biotechnology company developing next-generation antibody-based therapeutics, with a particular focus on antibody-drug conjugates and immuno-oncology applications. The company is built around proprietary platform technologies including TROCAD, a conditionally activatable domain designed to improve tumor-selective delivery and reduce off-tumor toxicity, and TROSIG, a linker-payload system designed to improve ADC stability, hydrophilicity, and payload release. TriOar appears to operate primarily as a platform and partnership-driven oncology biotech rather than a company built around a disclosed late-stage internal asset portfolio. Its capabilities span discovery biology, antibody screening, chemistry, linker-payload design, and preclinical evaluation. The company has raised venture funding, joined JLABS programs, and has disclosed a major platform technology transfer and joint development agreement with Celltrion.